Argus Upgrades GlaxoSmithKline (GSK) to Buy
Tweet
Share
E-mailGet Alerts GSK Hot Sheet
Price: $40.97 +0.27%
Rating Summary:
8 Buy, 13 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Rating Summary:
8 Buy, 13 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Join SI Premium – FREE
Argus upgraded GlaxoSmithKline (NYSE: GSK) from Hold to Buy.
For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $55.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
- JPMorgan Upgrades Doximity Inc (DOCS) to Neutral 'Given a More Stabilized Macro Backdrop and Little Downside to Our Valuation'
- Procter & Gamble (PG) PT Raised to $185 at Argus
Create E-mail Alert Related Categories
UpgradesRelated Entities
ArgusSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
